Stay updated on Nivolumab and SRS in Recurrent Meningioma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab and SRS in Recurrent Meningioma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab and SRS in Recurrent Meningioma Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    New update dates were added (2025-12-09, 2026-01-06, 2025-12-06, 2025-12) and older timestamps removed, with no substantive changes to the study details.
    Difference
    0.2%
    Check dated 2025-12-09T16:58:34.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    Added explicit primary and secondary objectives for the Phase I/II trial, including maximum tolerated combination safety and MRI-based objective response rate, and extended follow-up timing (treatment start to at least two years) with associated imaging and biomarker assessments. Also clarified or updated study procedures (MRI, blood sample collection, echocardiography) and removed certain earlier timepoint references such as 'Up to 100 days'.
    Difference
    0.5%
    Check dated 2025-12-02T16:25:40.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    Revision updated to v3.3.2; previous v3.2.0 has been removed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2025-11-25T13:32:05.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    The only change is the removal of a general government funding status notice; there are no edits to core study information, eligibility criteria, or trial data. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2025-11-18T07:18:04.000Z thumbnail image
  5. Check
    39 days ago
    Change Detected
    Summary
    Minor update to the Study Record dates/text; core study content such as eligibility criteria, endpoints, and treatment arms remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2025-11-03T21:21:34.000Z thumbnail image
  6. Check
    68 days ago
    Change Detected
    Summary
    Added a government funding lapse notice and a v3.2.0 version tag, replacing the prior v3.1.0.
    Difference
    2%
    Check dated 2025-10-06T05:49:10.000Z thumbnail image

Stay in the know with updates to Nivolumab and SRS in Recurrent Meningioma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab and SRS in Recurrent Meningioma Clinical Trial page.